Effect of PNS on Mobilizing Bone-marrow Mesenchymal Stem Cells in Rats
|Zhang Baoxia*, Zhang Jinsheng, Du Meimei, Wang Xiaoya, and Li Wei|
|Henan College of Traditional Chinese Medicine, Zhen Zhou, China|
|Corresponding Author :||Zhang Baoxia
Henan College of Traditional Chinese Medicine
Zhen Zhou, China – 450008
E-mail: [email protected]
|Received October 14, 2014; Accepted November 14, 2014; Published January 03, 2015|
|Citation: Baoxia Z, Jinsheng Z, Meimei Du, Xiaoya W, Wei Li (2015) Effect of PNS on Mobilizing Bone-marrow Mesenchymal Stem Cells in Rats. Nat Prod Chem Res 3:161. doi: 10.4172/2329-6836.1000161|
|Copyright: © 2015 Baoxia Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Objective: To investigate the effects of panax notoginseng saponins on mobilizing bone marrow mesenchymal stem cells after cerebral infarction so as to provide experimental basis for Huoxue Huayu Decoction (HXHYD) that is promoting the blood flow and removing blood stasis.
Methods: Apart from the normal group, all of the remaining rats must survive the improved Zea-Longa middle cerebral artery occlusion (MCAO) modeling method; all standard rats were randomly divided into four groups. The first group designated as control group was administered with normal saline by gavage every day. The second, third and fourth groups designated as drug groups were administered respectively with Xuesaitong soft Capsule (ingredients dissolved in normal saline) in 20, 40 and 60 mg/ml body weight/day (low-dose group, mid-dose group and high-dose group). The treatment continued for 28 days. Each group was then divided into subgroups (each subgroup contains at least 8 rats) determined by time points (1st day 3rd day 7th day 14th day and 28th day). Changes of CD54, CD106, CD105, CD117 in blood and bone marrow of rats were detected by FCM. The SCF level at different time points were determined though ELISA methods.
Results: The stem cell factor (SCF) level in peripheral blood and bone marrow showed a significant increase in the control group and the treated group. The SCF in peripheral blood and bone marrow increased on the 1st day and reached a peak on the 14th day, then decreased in the peripheral blood gradually. The SCF level in peripheral blood showed a better increase in both medium-dose and high-dose groups than that of model group (p<0.05). The levels of CD54, CD106, CD105 and CD117 in peripheral blood and bone marrow in the control group and treated groups reached a peak on the 1st day, and then decreased gradually. There was a significant increase compared with the normal group (p<0.05). The levels of CD54, CD106, CD105 and CD117 in peripheral blood and bone marrow in medium-dose and high-dose groups showed a positive increase (p<0.05) than those of the control group at each time point. Meanwhile there was no significant difference of CD54, CD106, CD105 and CD117 (p>0.05) between the lowdose group and the control group at each time point.
Conclusion: PNS can mobilize the BMSCs to improve the levels in the peripheral blood.